CRMD Down 31% in a Month: Is This an Indication to Sell the Stock?
CorMedixCorMedix(US:CRMD) ZACKS·2026-01-30 22:40

Key Takeaways CorMedix's shares fell 31% in a month after management issued conservative 2026 revenue guidance.CRMD guided 2026 revenues of 300−300-320M, with DefenCath sales expected to be 150−150-170 million.CRMD added diversification via the Melinta deal, with seven drugs and likely near-term growth from Rezzayo.Shares of CorMedix (CRMD) have declined sharply over the past month, reflecting investor concerns following its bearish 2026 financial outlook. The guidance points to a more conservative growth traje ...